BMI View: Pharmaceutical sales in Belarus are poised to recover as the fallout from the breaking of the
potash joint venture Uralkai-Belaruskali subsides, and the risk of currency devaluation temporarily relents.
However, Belarus must now contend with the consequences ..."
BMI View: Owing to new historical data, which indicated that sales of medicines in Belarus's hospitals in
particular grew more than previously expected, we have upwardly revised our top-line figures for the
country's drug market. Moreover, H1 2013 data for pharmaceuti ..."
BMI View: We have decided not to alter our near-term outlook for the Belarusian pharmaceutical market this quarter. We continue to regard factors such as local currency devaluation, state dominance in pharmaceutical manufacturing and regulatory bias against foreign producers as b ..."
BMI View: We view Belarus's pharmaceutical market as having modest longer-term potential, although
this potential will continue to be hampered by factors such as insufficient healthcare provision and a
challenging intellectual property (IP) environment. Although the authorities ..."
BMI View: We expect the volatility in the performance of the Belarusian pharmaceutical market to continue, with political tensions increasing risks to our forecasts. Although the government aims to increase local output and meet at least half of domestic drug demand, we note that ..."
We remain largely pessimistic about the Belarus' pharmaceutical market development in the short term at least. While the government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint venture (JV) discussions ..."
We remain largely pessimistic about Belarus's pharmaceutical market development, at least in the short term. The government remains committed to boosting domestic pharmaceutical output over the coming years, with authorities in manufacturing joint ..."